Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state

Cancer Discovery

Volumn 6, Issue 3, 2016, Pages 316-329

  Patricelli, Matthew P ^a   Janes, Matthew R ^a   Li, Lian Sheng ^a   Hansen, Rasmus ^a   Peters, Ulf ^a   Kessler, Linda V ^a   Chen, Yuching ^a   Kucharski, Jeff M ^a   Feng, Jun ^a   Ely, Tess ^a   Chen, Jeffrey H ^a   Firdaus, Sarah J ^a   Babbar, Anjali ^a   Ren, Pingda ^a,b   Liu, Yi ^a,b  

^a Wellspring Biosciences   (United States)

^b Kura Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; CYSTEINE; DIMETHYL SULFOXIDE; ERLOTINIB; GUANOSINE TRIPHOSPHATE; KRAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PEPTIDES AND PROTEINS; RAS PROTEIN; SHORT HAIRPIN RNA; SOS PROTEIN; TRAMETINIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; LIGAND; PROTEIN KINASE INHIBITOR; RECOMBINANT PROTEIN;

ARTICLE; ASSAY; CELL FUNCTION; CELL PROLIFERATION ASSAY; COLONY FORMATION ASSAY; DNA SEQUENCE; ELECTROSPRAY MASS SPECTROMETRY; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; G12C CELL ENGAGEMENT ASSAY; GENE ACTIVATION; GENE MUTATION; HUMAN; HUMAN CELL; IC50; KRAS BIOCHEMICAL MODIFICATION ASSAY; KRAS GENE; LIQUID CHROMATOGRAPHY; NONHUMAN; NUCLEOTIDE EXCHANGE ASSAY; ONCOGENE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROXIMITY LIGATION ASSAY; RBD MS ASSAY; RBD PULLDOWN ASSAY; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TIME OF FLIGHT MASS SPECTROMETRY; X RAY CRYSTALLOGRAPHY; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CELL TRANSFORMATION; CHEMISTRY; CONFORMATION; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; GENETICS; METABOLISM; MOLECULAR MODEL; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BIOMARKERS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LIGANDS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PROTEIN KINASE INHIBITORS; RAS PROTEINS; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84958640923     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-15-1105     Document Type: Article

References (31)

1. Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov 2014; 13: 828-51
2. Sun Q, Burke JP, Phan J, Burns MC, Olejniczak ET, Waterson AG, et al. Discovery of small molecules that bind to K-Ras and inhibit Sosmediated activation. Angewandte Chemie 2012; 51: 6140-3
3. Maurer T, Garrenton LS, Oh A, Pitts K, Anderson DJ, Skelton NJ, et al. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc Natl Acad Sci U S A 2012; 109: 5299-304
4. Shima F, Yoshikawa Y, Matsumoto S, Kataoka T. Discovery of smallmolecule Ras inhibitors that display antitumor activity by interfering with Ras.GTP-effector interaction. Enzymes 2013; 34 Pt. B: 1-23
5. Lim SM, Westover KD, Ficarro SB, Harrison RA, Choi HG, Pacold ME, et al. Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor. Angewandte Chemie 2014; 53: 199-204
6. Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013; 503: 548-51
7. Wang C, Weerapana E, Blewett MM, Cravatt BF. A chemoproteomic platform to quantitatively map targets of lipid-derived electrophiles. Nat Methods 2014; 11: 79-85
8. Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N, et al. A gene expression signature associated with “K-Ras addiction” reveals regulators of EMT and tumor cell survival. Cancer Cell 2009; 15: 489–500
9. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 2011; 17: 500-3
10. Foster R, Mudd C, Wiggins C, Torrance C. Abstract 4289: 3-Dimensional growth reveals KRAS dependency. Cancer Res 2013; 73: 4289
11. Fujita-Sato S, Galeas J, Truitt M, Pitt C, Urisman A, Bandyopadhyay S, et al. Enhanced MET translation and signaling sustains K-Ras driven proliferation under anchorage-independent growth conditions . Cancer Res 2015; 75: 2851-62
12. Vartanian S, Bentley C, Brauer MJ, Li L, Shirasawa S, Sasazuki T, et al. Identification of mutant K-Ras-dependent phenotypes using a panel of isogenic cell lines. J Biol Chem 2013; 288: 2403-13
13. Ahmadian MR, Zor T, Vogt D, Kabsch W, Selinger Z, Wittinghofer A, et al. Guanosine triphosphatase stimulation of oncogenic Ras mutants. Proc Natl Acad Sci U S A 1999; 96: 7065-70
14. Hunter JC, Manandhar A, Carrasco MA, Gurbani D, Gondi S, Westover KD. Biochemical and Structural Analysis of Common Cancer- Associated KRAS Mutations. Mol Cancer Res 2015; 13: 1325-35
15. Alessi DR, Saito Y, Campbell DG, Cohen P, Sithanandam G, Rapp U, et al. Identification of the sites in MAP kinase kinase-1 phosphorylated by p74raf-1. EMBO J 1994; 13: 1610–9
16. Dougherty MK, Muller J, Ritt DA, Zhou M, Zhou XZ, Copeland TD, et al. Regulation of Raf-1 by direct feedback phosphorylation. Mol Cell 2005; 17: 215-24
17. Pratilas CA, Taylor BS, Ye Q, Viale A, Sander C, Solit DB, et al. (V600E)BRAF is associated with disabled feedback inhibition of RAFMEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A 2009; 106: 4519-24
18. Sun C, Hobor S, Bertotti A, Zecchin D, Huang S, Galimi F, et al. Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. Cell Rep 2014; 7: 86–93
19. Montero-Conde C, Ruiz-Llorente S, Dominguez JM, Knauf JA, Viale A, Sherman EJ, et al. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov 2013; 3: 520-33
20. Molina-Arcas M, Hancock DC, Sheridan C, Kumar MS, Downward J. Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer. Cancer Discov 2013; 3: 5 48–63
21. Trahey M, McCormick F. A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Science 1987; 238: 542-5
22. Ford B, Skowronek K, Boykevisch S, Bar-Sagi D, Nassar N. Structure of the G60A mutant of Ras: implications for the dominant negative effect. J Biol Chem 2005; 280: 25697-705
23. Buss JE, Solski PA, Schaeffer JP, MacDonald MJ, Der CJ. Activation of the cellular proto-oncogene product p21Ras by addition of a myristylation signal. Science 1989; 243: 1600-3
24. Adari H, Lowy DR, Willumsen BM, Der CJ, McCormick F. Guanosine triphosphatase activating protein (GAP) interacts with the p21 ras effector binding domain. Science 1988; 240: 518-21
25. Young A, Lou D, McCormick F. Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. Cancer Discov 2013; 3: 112-23
26. Evelyn CR, Biesiada J, Duan X, Tang H, Shang X, Papoian R, et al. Combined rational design and a high throughput screening platform for identifying chemical inhibitors of a Ras-activating enzyme. J Biol Chem 2015; 290: 12879-98
27. Patgiri A, Yadav KK, Arora PS, Bar-Sagi D. An orthosteric inhibitor of the Ras-Sos interaction. Nat Chem Biol 2011; 7: 585-7
28. Leshchiner ES, Parkhitko A, Bird GH, Luccarelli J, Bellairs JA, Escudero S, et al. Direct inhibition of oncogenic KRAS by hydrocarbonstapled SOS1 helices. Proc Natl Acad Sci U S A 2015; 112: 1761-6
29. Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, et al. Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr 2011; 67: 235-42
30. Chen VB, Arendall WB 3rd, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr 2010; 66: 12–21
31. Johnson KA. Fitting enzyme kinetic data with KinTek global kinetic explorer. Methods Enzymol 2009; 467: 601-26.